DGAP-Ad-hoc: Evotec SE / Key word(s): Study results 
Evotec SE: Positive Phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough 
03-Aug-2021 / 14:19 CET/CEST 
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480) announces that 
the Company has been informed by Bayer about positive Phase IIb results from a clinical trial evaluating the efficacy 
and safety of the investigational P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic 
cough. The underlying molecule is a P2X3 receptor antagonist in Bayer's clinical development pipeline originating from 
a former Evotec/Bayer multi-target research alliance. The primary efficacy outcome was met showing a statistically 
significant improvement in 24-hour cough counts per hour (average hourly cough frequency based on 24-hour sound 
recordings) over placebo after 12 weeks of treatment. The data showed a favourable safety and tolerability profile. 
Under the agreement from 2012, Evotec would be entitled to its next financial milestone payment upon start of a Phase 
III clinical study, to be decided by Bayer. 
More details of the study will be presented by Bayer. 
- End of ad hoc release - 
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, 
Germany, Phone: +49.(0)40.560 81-242, werner.lanthaler@evotec.com 
=---------------------------------------------------------------------------------------------------------------------- 
03-Aug-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and 
Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Evotec SE 
              Manfred Eigen Campus / Essener Bogen 7 
              22419 Hamburg 
              Germany 
Phone:        +49 (0)40 560 81-0 
Fax:          +49 (0)40 560 81-222 
E-mail:       info@evotec.com 
Internet:     www.evotec.com 
ISIN:         DE0005664809 
WKN:          566480 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1223677 
 
End of Announcement  DGAP News Service 
=------------

1223677 03-Aug-2021 CET/CEST


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1223677&application_name=news

(END) Dow Jones Newswires

August 03, 2021 08:20 ET (12:20 GMT)